Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational aqueous solution is a combination of the phytocannabinoids cannabidiol (CBD) and cannabinol (CBN), developed by Wroclaw Medical University for the treatment of chronic facial pain and headaches of muscular origin. CBD and CBN are non-psychoactive or mildly psychoactive compounds derived from the Cannabis sativa plant that interact with the endocannabinoid system to modulate pain signaling and inflammatory responses. The formulation is administered orally, with dosing determined by a physician, and is currently being evaluated in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT05961501) to assess its efficacy in reducing pain intensity and improving muscle function as measured by electromyography and pressure pain threshold tests.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cannabidiol + cannabinol (Wroclaw Medical University).